Rodgersbonner7675

Z Iurium Wiki

Verze z 15. 11. 2024, 22:27, kterou vytvořil Rodgersbonner7675 (diskuse | příspěvky) (Založena nová stránka s textem „falciparum. In molecular docking studies, both compounds bind into the active site of PfFP-2 and block its accessibility to the substrate that leads to the…“)
(rozdíl) ← Starší verze | zobrazit aktuální verzi (rozdíl) | Novější verze → (rozdíl)

falciparum. In molecular docking studies, both compounds bind into the active site of PfFP-2 and block its accessibility to the substrate that leads to the inhibition of target protein further supported by in-vitro analysis. Overall, we report antimalarial potential of triazole-amino acid hybrids and their role in the inhibition of cysteine protease PfFP-2 as its mechanistic aspect. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Dryopteris cycadina has diverse traditional uses in the treatment of various human disorders which are supported by pharmacological studies. Similarly, the phytochemical studies of this plant led to the isolation of numerous compounds. The present study deals with α-glucosidase inhibition of various kaempferol derivates including kaempferol-3, 4/-di-O-α- L-rhamnopyranoside 1, kaempferol-3, 5-di-O-α-L-rhamnoside 2 and kaempferol-3,7-di-O-α- L-rhamnopyranoside 3. The results showed marked concentration-dependent inhibition of the enzyme when assayed at different concentration and the IC50 values of compounds 1-3 were137±9.01, 110±7.33, and 136±1.10 mM, respectively far better than standard compound, acarbose 290±0.54 mM. The computational studies revealed strong docking scores of these compounds and augmented the in vitro assay. In conclusion, the isolated kaempferol derivatives 1-3 from D. cycadina exhibited potent α-glucosidase inhibition. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Nutraceuticals are dietary supplements, dietary fiber utilized to ameliorate health, delay senescence, prevent diseases, and support proper functioning of human body. Currently nutraceuticals are getting substantial attention due to nutrition and therapeutic potentials. They have benefit over medicine because they avoid side effect. On the basis of their source, they are categories into different terms such as nutrients, dietary supplements, herbals, dietary fiber, etc. Global market for nutraceutical is huge i.e approximately USD 117 billion. Herbal nutraceutical is a powerful tool in maintaining health and to act against nutritionally induced diseases, thus promoting optimal health, longevity, and quality of life. Studies have shown promising results of nutraceuticals to treat several diseases such as cancer, neurodegenative diseases, cardiovascular diseases, etc. In the present review an overview of various bioactive ingredients which act as nutraceuticals (carbohydrates, lipids, edible flowers, alkaloids, medicinal plants, etc.) and their role in health benefits has been discussed. learn more Further application of nutraceuticals in various diseases prevention has been also discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Amylases enzymes hydrolyze starch molecules to producediverse products including dextrins, and progressively smaller polymers. These include glucose units linked through α-1-1, α-1-4, α-1-6, glycosidic bonds. This enzyme carry an (α /β) 8 or TIM barrel structure ia also produced containing the catalytic site residues.These groups of enzymespossess four conserved regions in their primary sequence. In the carbohydrate-degrading enzyme(CAZy) database, α-amylases are classified into different glycoside hydrolase families (GHF) based on their amino acid sequence. Present objectives were to study on one such enzyme based on its molecular characterization after it purification in our laboratory. Its main property of solid-natural starch degradation was extensively investigated for its pharmaceutical/ industrialapplications.Amylase producing bacteria Bacillus cereus sm-sr14 (Accession no. KM251578.1) was purified to homogeneity on a Seralose 6B-150 gel-matrix and gave a single peak during HPLC. MALDI-TOF mass-spectrometry with bioinformatics studies revealed its significant similarity to α/β hydrolase family. The enzyme showed a very high application-favourable Km,Vmax and Kcat during the catalysis of different natural solid starch materials. Analysis for hydrolytic product showed that this enzyme can be classified as the exoamylaseas because it produced significant amount of glucose.Beside the purified enzyme, the present whole organism Bacillus cereus sm-sr14 could degrade natural solid starch materials like potato, rice up to the application level in pharmaceutical/ industrial field for alcohol production. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Melanoma is the deadliest type of skin cancers, accounting for more than 80% of skin cancer mortality. Although melanoma was known very early in the history of medicine, treatment for this disease had remained largely the same until very recently. Previous treatment options, including removal surgery and systemic chemotherapy, offered little benefit in extending the survival of melanoma patients. However, the last decade has seen breakthroughs in melanoma treatment, which all emerged following new insight into the oncogenic signalling of melanoma. This paper reviewed the evolution of drug targets for melanoma treatment based on the emergence of novel findings in the molecular signalling of melanoma. One of the findings that are most influential in melanoma treatment is that more than 50% of melanoma tumors contain BRAF mutations. This is fundamental for the development of BRAF inhibitors, which is the first group of drugs that significantly improve the overall survival of melanoma patients compared to the traditional chemotherapeutic dacarbazine. More recently, findings of the role of immune checkpoint molecules such as CTLA-4 and PD1/PD-L1 in melanoma biology have led to the development of a new therapeutic category immune checkpoint inhibitors, which, for the first time in the history of cancer treatment, produced a durable response in a subset of melanoma patients. However, as this paper discussed next, there is still an unmet need in melanoma treatment. A significant population of patients did not respond to either BRAF inhibitors or immune checkpoint inhibitors. Of those patients who gained an initial response from those therapies, a remarkable percentage would develop drug resistance even when MEK inhibitors were added to the treatment. Finally, this paper discusses some possible targets for melanoma treatment. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Autoři článku: Rodgersbonner7675 (Hein Pickett)